rfp2 Antibody

What is RFP2 and what cellular functions does it participate in?

RFP2 (also known as TRIM13) is a protein encoded by the TRIM13 gene that belongs to the tripartite motif-containing family. The human version has a canonical amino acid length of 407 residues and a molecular weight of approximately 47 kilodaltons, with three identified isoforms. This protein functions in multiple biological processes including morphogenesis of anatomical structures and innate immune responses. RFP2 is predominantly localized in the endoplasmic reticulum (ER) of cells and shows notable expression in various tissues including the cerebral cortex and fallopian tubes. In the scientific literature, RFP2 is also referred to by several alternative names including CAR, DLEU5, and LEU5, which researchers should be aware of when conducting literature searches and designing experiments .

What types of RFP2 antibodies are available for research applications?

RFP2 antibodies are available in multiple formats optimized for different experimental applications. These include unconjugated antibodies suitable for Western blot, ELISA, immunohistochemistry, and immunofluorescence techniques. The antibodies vary in terms of their host species (commonly rabbit and mouse), clonality (monoclonal or polyclonal), and specific reactivity profiles. For instance, some antibodies specifically target the middle region of the RFP2 protein. Commercially available RFP2 antibodies demonstrate varied cross-reactivity patterns across species, with some showing reactivity to human, mouse, rat, bovine, and dog samples, while others may have more limited species reactivity. When selecting an antibody, researchers should carefully consider the target species, the specific application requirements, and whether a monoclonal or polyclonal antibody would be more appropriate for their experimental design .

How should researchers validate the specificity of RFP2 antibodies?

Validating antibody specificity is critical for ensuring experimental rigor. For RFP2 antibodies, a multi-step validation approach is recommended. First, researchers should perform Western blot analysis using positive controls (tissues or cell lines known to express RFP2, such as cerebral cortex samples) and negative controls (knockout cell lines or tissues where RFP2 expression is absent). The antibody should detect a band at approximately 47 kDa, corresponding to the canonical RFP2 protein. For further validation, immunoprecipitation followed by mass spectrometry can confirm the identity of the pulled-down protein. Additionally, immunohistochemistry or immunofluorescence staining should show expected ER localization patterns. Researchers should also be aware of potential cross-reactivity with other TRIM family members due to structural similarities, and should use blocking peptides specific to RFP2 to confirm signal specificity. Finally, utilizing siRNA knockdown of RFP2 followed by immunoblotting provides a powerful method to confirm antibody specificity in cellular contexts .

What are the optimal conditions for using RFP2 antibodies in Western blot applications?

For optimal Western blot results with RFP2 antibodies, several methodological considerations are crucial. Sample preparation should include complete lysis buffers containing protease inhibitors to prevent degradation of the 47 kDa RFP2 protein. For gel electrophoresis, 10-12% SDS-PAGE gels typically provide adequate resolution for RFP2. During transfer, PVDF membranes often yield better results than nitrocellulose for this protein. For blocking, 5% non-fat dry milk in TBST (Tris-buffered saline with 0.1% Tween-20) for 1 hour at room temperature is generally effective. Primary antibody incubation should be performed at dilutions between 1:500 and 1:2000 (depending on the specific antibody), overnight at 4°C. For detection, both chemiluminescence and fluorescence-based methods are suitable, though fluorescence may offer better quantification capabilities. Positive controls should include cell lines known to express RFP2, while negative controls might utilize RFP2-knockdown samples. Due to potential cross-reactivity with other TRIM family proteins, researchers should carefully evaluate band patterns and consider confirmatory experiments with alternative antibodies targeting different epitopes of RFP2 .

How can researchers optimize immunohistochemistry protocols for RFP2 detection in tissue samples?

Optimizing immunohistochemistry (IHC) for RFP2 detection requires careful attention to several protocol elements. For tissue fixation, 4% paraformaldehyde is generally recommended, as overfixation may mask the RFP2 epitope. Antigen retrieval is crucial, with heat-induced epitope retrieval in citrate buffer (pH 6.0) typically yielding good results. For paraffin-embedded sections, a 20-minute retrieval at 95-98°C is often effective. Blocking should include both protein blocking (3-5% BSA or normal serum) and peroxidase blocking (3% hydrogen peroxide) steps. Primary antibody incubation should be performed at dilutions between 1:100 and 1:500, overnight at 4°C. When optimizing, a titration experiment with multiple dilutions is advisable. For visualization, both chromogenic (DAB) and fluorescent detection systems work well with RFP2 antibodies. Counterstaining with hematoxylin (for chromogenic detection) should be light to avoid obscuring the RFP2 signal. When interpreting results, researchers should expect predominantly endoplasmic reticulum staining patterns, with notable expression in cerebral cortex and certain epithelial tissues. Validation controls should include blocking peptides and comparison with RNA expression data from the same tissues .

What are the key considerations for using RFP2 antibodies in co-immunoprecipitation experiments?

Co-immunoprecipitation (Co-IP) experiments with RFP2 antibodies require specific optimization for successful protein complex isolation. The choice of lysis buffer is critical—a mild, non-denaturing buffer (e.g., 1% NP-40 or 0.5% Triton X-100 in Tris-buffered saline) helps preserve protein-protein interactions while effectively extracting RFP2 from the endoplasmic reticulum. Pre-clearing the lysate with protein A/G beads (30-60 minutes at 4°C) reduces non-specific binding. For RFP2 antibody coupling, 2-5 μg of antibody per 500 μg of protein lysate is typically effective, with overnight incubation at 4°C with gentle rotation. As RFP2 functions in protein complexes involved in morphogenesis and immune responses, the binding conditions must be carefully optimized to maintain these interactions. Washing steps should be gentle (3-4 washes with lysis buffer containing reduced detergent concentration) to preserve specific interactions while removing background. For elution, both acidic (pH 2.5-3.0 glycine buffer) and denaturing (SDS sample buffer) methods can be used, though the former better preserves interacting partners for downstream analysis. Western blot analysis of the immunoprecipitated material should detect both RFP2 (47 kDa) and its known interacting partners. Mass spectrometry analysis of co-immunoprecipitated proteins can identify novel RFP2 interaction partners in specific cellular contexts .

How can researchers utilize RFP2 antibodies in studying protein-protein interactions within the TRIM family network?

Investigating RFP2 (TRIM13) interactions within the broader TRIM protein network requires sophisticated applications of RFP2 antibodies. Proximity ligation assays (PLA) represent a powerful approach, where RFP2 antibodies are combined with antibodies against suspected interacting TRIM family members. This technique can visualize protein interactions in situ with subcellular resolution, revealing the endoplasmic reticulum-specific interactions of RFP2. For mapping the complete interactome, BioID or APEX2 proximity labeling can be employed by fusing these enzymes to RFP2 and using antibodies to verify expression and localization. When studying dynamic interactions, fluorescence resonance energy transfer (FRET) or bimolecular fluorescence complementation (BiFC) combined with immunofluorescence validation using RFP2 antibodies can reveal condition-specific interactions. For functional studies, researchers should consider comparing wild-type conditions with those where specific domains of RFP2 have been mutated, using antibodies to confirm expression levels before interpreting phenotypic changes. When analyzing data, it's important to distinguish direct interactions from indirect associations within the same complex by complementing antibody-based techniques with in vitro binding assays. This multi-method approach is essential given RFP2's involvement in diverse cellular processes including morphogenesis and innate immune responses .

What methodological approaches can be used to study RFP2 post-translational modifications using RFP2 antibodies?

Studying post-translational modifications (PTMs) of RFP2 requires specialized methodological approaches with RFP2 antibodies. For phosphorylation analysis, researchers should first immunoprecipitate RFP2 using validated antibodies, followed by Western blotting with phospho-specific antibodies or phospho-protein staining (e.g., ProQ Diamond). Mass spectrometry analysis of immunoprecipitated RFP2 provides comprehensive PTM mapping; this approach has revealed phosphorylation sites that potentially regulate RFP2's function in immune response pathways. For ubiquitination studies, denaturing conditions (8M urea or 1% SDS) in the lysis buffer are essential before dilution for immunoprecipitation to disrupt associated deubiquitinases. After RFP2 immunoprecipitation, Western blotting with anti-ubiquitin antibodies can reveal modification patterns. SUMOylation analysis follows similar protocols but uses SUMO-specific antibodies. For studying dynamic changes in PTMs, researchers should perform time-course experiments after appropriate stimuli (e.g., immune activators), immunoprecipitating RFP2 at different time points. Phosphatase or deubiquitinase inhibitors should be included in lysis buffers to preserve modifications. When interpreting results, it's important to distinguish between direct modification of RFP2 and co-precipitating modified proteins by performing reverse immunoprecipitations with PTM-specific antibodies followed by RFP2 detection. These methods can reveal how PTMs regulate RFP2's localization to the endoplasmic reticulum and its function in morphogenesis and immune response pathways .

How can super-resolution microscopy be optimized when using RFP2 antibodies for subcellular localization studies?

Optimizing super-resolution microscopy with RFP2 antibodies requires careful consideration of several technical factors. For sample preparation, light fixation (2-4% paraformaldehyde for 10-15 minutes) better preserves the endoplasmic reticulum structure where RFP2 localizes, while maintaining epitope accessibility. When selecting primary RFP2 antibodies, those validated for immunofluorescence with minimal background are essential; monoclonal antibodies often provide more specific labeling for super-resolution techniques. For secondary antibody selection, highly cross-adsorbed antibodies conjugated to bright, photostable fluorophores appropriate for the specific super-resolution technique are recommended (e.g., Alexa Fluor 647 for STORM, ATTO 488 for STED). For multicolor imaging, co-labeling with established ER markers (e.g., calnexin, PDI) can provide crucial contextual information and validation of RFP2 localization patterns. When using techniques like STORM or PALM, a buffer system containing an oxygen scavenging system (glucose oxidase/catalase) and appropriate reducing agent (MEA or BME) optimizes the photoswitching behavior of the fluorophores. For image acquisition, sampling at 10-20 nm pixel size is typically required to fully leverage the resolution capabilities. During image analysis, clustering algorithms can be applied to quantify the nanoscale distribution of RFP2 within the ER membrane, potentially revealing functional microdomains. Comparative analysis between different cell types or experimental conditions should use consistent imaging and analysis parameters to ensure valid comparisons of RFP2 distribution patterns .

What strategies can researchers employ when faced with non-specific binding of RFP2 antibodies?

Non-specific binding of RFP2 antibodies can significantly compromise experimental results. To address this issue, researchers should implement a multi-faceted optimization strategy. First, antibody titration experiments should be performed to determine the minimum effective concentration, as excessive antibody concentrations often increase background. For Western blotting, increasing the stringency of washing steps (using TBST with up to 0.3% Tween-20) and extending washing duration can reduce non-specific binding. Adding blocking proteins to the antibody dilution buffer (5% BSA or milk) can also effectively reduce background. For immunoprecipitation, pre-clearing lysates with Protein A/G beads before adding the RFP2 antibody removes proteins that non-specifically bind to the beads. When non-specific bands persist in Western blots, competitive blocking with the immunizing peptide can help identify which bands represent specific RFP2 detection. For immunohistochemistry or immunofluorescence, autofluorescence or endogenous peroxidase activity should be quenched appropriately. When possible, validating results with a second RFP2 antibody targeting a different epitope provides powerful confirmation of specificity. If cross-reactivity with other TRIM family proteins is suspected due to sequence homology, researchers should perform parallel experiments in systems where RFP2 expression has been knocked down or knocked out to confirm which signals are specific .

What are the best practices for long-term storage and handling of RFP2 antibodies to maintain optimal performance?

Maintaining optimal performance of RFP2 antibodies over time requires adherence to specific storage and handling best practices. For long-term storage, antibodies should be kept at -20°C or -80°C in small aliquots (10-50 μL) to minimize freeze-thaw cycles, as repeated freezing and thawing can lead to antibody denaturation and reduced activity. Working aliquots should be stored at 4°C with appropriate preservatives (0.02-0.05% sodium azide) to prevent microbial contamination while avoiding higher concentrations that might interfere with certain applications like immunohistochemistry. Before each use, antibodies should be gently mixed rather than vortexed to prevent protein denaturation and aggregate formation. Centrifugation of the antibody solution before use (10,000 × g for 5 minutes) can remove any aggregates that might cause background issues. For diluted antibody solutions, BSA (0.1-1%) should be added as a carrier protein to prevent adsorption to container surfaces and maintain antibody stability. Researchers should maintain detailed records of antibody performance over time, including optimal dilutions for different applications, to track any potential deterioration. If diminished performance is observed, comparing the current results with historical positive controls can help determine whether the issue is antibody degradation or another experimental variable. For antibodies showing reduced activity, concentration via centrifugal filters may restore performance in some cases. Finally, when using antibodies near their expiration date, validation with positive controls becomes particularly important to ensure experimental reliability .

How can RFP2 antibodies be utilized in studying neurodegenerative disease mechanisms?

RFP2 antibodies offer valuable tools for investigating neurodegenerative disease mechanisms, particularly given RFP2's expression in the cerebral cortex and potential roles in protein quality control. When studying neurodegenerative models, immunohistochemistry with RFP2 antibodies can reveal alterations in expression patterns or subcellular localization that may correlate with disease progression. Double immunofluorescence labeling combining RFP2 antibodies with markers for aggregated proteins (tau, α-synuclein, or amyloid-β) can determine whether RFP2 co-localizes with pathological inclusions, potentially indicating involvement in proteostasis mechanisms. In models of ER stress—a common feature in neurodegeneration—Western blotting with RFP2 antibodies can quantify expression changes in response to stressors, while fractionation studies can track potential redistribution between cellular compartments. For functional studies, co-immunoprecipitation with RFP2 antibodies followed by mass spectrometry can identify disease-specific interaction partners in brain tissue samples. When designing these experiments, age-matched controls are essential, as RFP2 expression may naturally change with aging. Researchers should also consider region-specific analyses, as neurodegenerative diseases often affect brain regions differentially. Quantitative analyses should employ digital image analysis software to objectively measure co-localization coefficients or expression levels across experimental groups. These approaches can provide insights into whether alterations in RFP2 function contribute to neurodegeneration through dysregulated morphogenesis or compromised quality control mechanisms .

What methodological approaches should be used when employing RFP2 antibodies in cancer research studies?

In cancer research, RFP2 antibodies can be applied through several methodological approaches to investigate its potential tumor suppressor functions. For tissue microarray studies, immunohistochemistry with RFP2 antibodies allows high-throughput analysis of expression patterns across tumor types and grades, with digital pathology quantification providing objective scoring. In cell line models, Western blotting should be performed across panels of normal and cancer cell lines to establish baseline expression patterns before experimental manipulation. When studying RFP2's subcellular localization in tumor cells, confocal microscopy with dual labeling (RFP2 and organelle markers) can reveal cancer-associated mislocalization that might contribute to pathogenesis. For mechanistic studies, chromatin immunoprecipitation (ChIP) assays using RFP2 antibodies can identify genes directly regulated by RFP2 in different cancer contexts, particularly relevant if nuclear localization is observed. In xenograft models, immunohistochemistry with human-specific RFP2 antibodies can track expression in tumors during progression and in response to therapies. When analyzing clinical samples, researchers should correlate RFP2 expression with patient outcomes using appropriate statistical methods and multivariate analyses to account for confounding factors. For all cancer research applications, validation of RFP2 antibody specificity in the specific tumor type is essential, as altered post-translational modifications or splicing variants in cancer cells may affect epitope recognition. These approaches can help elucidate whether alterations in RFP2 expression or function contribute to oncogenesis through disrupted cellular morphogenesis or immune response pathways .

Data Table: Application-Specific Parameters for RFP2 Antibody Usage